| Followers | 52 |
| Posts | 14331 |
| Boards Moderated | 0 |
| Alias Born | 06/15/2014 |
Tuesday, December 24, 2024 7:57:24 AM
No question PBM is a heavyweight in small biotech investing. And of course as you mention Paul Manning who leads them is on the board at Candel and just sank a bunch of money into buying shares personally it seems.
For those who are not that familiar with CADL, this short talk with CEO Tak is a good primer:
If I had to pick a couple of things that were the least positive in that talk, I would say these would be it:
1) Around 5:40 mark, Tak talking about some clinical trial results are coming in the next qtr and "if several of these are positive".... - tough enough to have one study meet endpoints, so hoping for several positive results adds just a bit more anxiety to this. But hopefully past data dictates hope might be justified.
2) Although Tak mentions the path forward will probably involved BP in the form of partnerships, he seems to leave the U.S. market for CADL alone and talks about turning the company into a small Pharma. Although he worked for GSK and recognizes how BP has a much greater ability to drive sales, his mentioning of keeping the US for himself sends up red flags for me about GIA. I have seen that happen to so many small bios. Egos eventually doom the path forward.
Will be watching this closely.
For those who are not that familiar with CADL, this short talk with CEO Tak is a good primer:
If I had to pick a couple of things that were the least positive in that talk, I would say these would be it:
1) Around 5:40 mark, Tak talking about some clinical trial results are coming in the next qtr and "if several of these are positive".... - tough enough to have one study meet endpoints, so hoping for several positive results adds just a bit more anxiety to this. But hopefully past data dictates hope might be justified.
2) Although Tak mentions the path forward will probably involved BP in the form of partnerships, he seems to leave the U.S. market for CADL alone and talks about turning the company into a small Pharma. Although he worked for GSK and recognizes how BP has a much greater ability to drive sales, his mentioning of keeping the US for himself sends up red flags for me about GIA. I have seen that happen to so many small bios. Egos eventually doom the path forward.
Will be watching this closely.
Recent CADL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:08:06 PM
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/02/2026 08:05:00 PM
- Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors • GlobeNewswire Inc. • 03/17/2026 12:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/12/2026 12:58:28 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/12/2026 12:17:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 12:10:26 PM
- Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/12/2026 12:05:00 PM
- Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting • GlobeNewswire Inc. • 03/09/2026 12:05:00 PM
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/02/2026 09:05:00 PM
- Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston • GlobeNewswire Inc. • 02/24/2026 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 01:00:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/20/2026 09:16:14 PM
- Candel Therapeutics Announces Pricing of Public Offering • GlobeNewswire Inc. • 02/20/2026 02:40:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/19/2026 09:31:42 PM
- Candel Therapeutics Announces Proposed $100 Million Public Offering • GlobeNewswire Inc. • 02/19/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/19/2026 09:03:06 PM
- Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer • GlobeNewswire Inc. • 02/19/2026 09:01:00 PM
- Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit • GlobeNewswire Inc. • 02/11/2026 01:05:00 PM
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/02/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/28/2026 10:04:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/28/2026 10:02:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/28/2026 10:01:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/28/2026 10:00:12 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 01/21/2026 05:30:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2025 01:30:52 PM
